Oculis (NASDAQ:OCS) Hits New 1-Year High – Here’s Why

Shares of Oculis Holding AG (NASDAQ:OCS) hit a new 52-week high during trading on Friday . The stock traded as high as $25.21 and last traded at $25.16, with a volume of 154735 shares changing hands. The stock had previously closed at $23.84.

Analyst Upgrades and Downgrades

OCS has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. assumed coverage on Oculis in a report on Friday, December 19th. They set an “overweight” rating and a $38.00 price target for the company. Needham & Company LLC restated a “buy” rating and set a $36.00 target price on shares of Oculis in a research note on Tuesday, November 11th. Lifesci Capital started coverage on shares of Oculis in a research note on Wednesday, December 3rd. They issued an “outperform” rating and a $55.00 price target on the stock. Stifel Nicolaus boosted their price objective on shares of Oculis from $35.00 to $40.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oculis in a research report on Wednesday, October 8th. Eight equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Oculis has an average rating of “Moderate Buy” and a consensus price target of $41.50.

Oculis Trading Up 5.8%

The business’s 50-day moving average price is $20.24 and its 200-day moving average price is $19.09. The firm has a market capitalization of $1.32 billion, a PE ratio of -10.01 and a beta of 0.31. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.47 and a quick ratio of 4.47.

Oculis (NASDAQ:OCS) last issued its quarterly earnings results on Monday, November 10th. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.10. Oculis had a negative net margin of 12,915.42% and a negative return on equity of 80.82%. The firm had revenue of $0.31 million during the quarter, compared to analysts’ expectations of $0.23 million. As a group, analysts expect that Oculis Holding AG will post -2.09 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Oculis

Several institutional investors have recently added to or reduced their stakes in OCS. Compagnie Lombard Odier SCmA lifted its position in Oculis by 11.5% during the 2nd quarter. Compagnie Lombard Odier SCmA now owns 97,000 shares of the company’s stock worth $1,883,000 after acquiring an additional 10,000 shares during the period. Geode Capital Management LLC raised its stake in shares of Oculis by 27.7% during the second quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock worth $571,000 after purchasing an additional 6,384 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of Oculis during the second quarter worth $393,000. Bosun Asset Management LLC acquired a new stake in shares of Oculis during the second quarter worth $378,000. Finally, Bank of America Corp DE increased its stake in Oculis by 2.2% in the 2nd quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock valued at $786,000 after buying an additional 878 shares during the period. Institutional investors and hedge funds own 22.30% of the company’s stock.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.